Education
About Us
Working with TipRanks
Follow Us
Gri Bio, Inc. (GRI)
NASDAQ:GRI
GRI Stock Chart & Stats
$2.05
-$0.06(-7.48%)
At close: 4:00 PM EST
$2.05
-$0.06(-7.48%)
Day’s Range― - ―
52-Week Range$0.22 - $15.47
Previous CloseN/A
Volume96.89K
Average Volume (3M)3.29M
Market Cap
$2.83M
Enterprise Value$485.55K
Total Cash (Recent Filing)$4.05M
Total Debt (Recent Filing)$84.00K
Price to Earnings (P/E)―
Beta2.40
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding10,121,060
10 Day Avg. Volume7,033,414
30 Day Avg. Volume3,289,010
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.11
P/FCF Ratio-0.30
Enterprise Value/Market Cap0.17
Enterprise Value/Revenue0.08
Enterprise Value/Gross Profit-121.39
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$23.00Price Target Upside1021.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive interim data: In September 2025, the company reported positive 6-week interim lung function data with no decline in lung function observed and builds upon positive safety and biomarker data.
Financial StabilityBalance sheet: In Q3, GRI had $4 million in cash and no debt. In Q2, the company raised $5 million. Analysts believe it has enough cash into 2026.
Market PotentialLarge market potential for IPF: Idiopathic pulmonary fibrosis is one of the most common and severe forms of progressive PF. IPF is on the rise with more than 40,000 new cases diagnosed annually.
Bears Say
GRI Bio News
GRI FAQ
What was Gri Bio, Inc.’s price range in the past 12 months?
Gri Bio, Inc. lowest stock price was $0.22 and its highest was $15.47 in the past 12 months.
What is Gri Bio, Inc.’s market cap?
Gri Bio, Inc.’s market cap is $2.83M.
When is Gri Bio, Inc.’s upcoming earnings report date?
Gri Bio, Inc.’s upcoming earnings report date is May 20, 2026 which is in 134 days.
How were Gri Bio, Inc.’s earnings last quarter?
Gri Bio, Inc. released its earnings results on Aug 13, 2025. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.31 by -$0.08.
Is Gri Bio, Inc. overvalued?
According to Wall Street analysts Gri Bio, Inc.’s price is currently Undervalued.
Does Gri Bio, Inc. pay dividends?
Gri Bio, Inc. does not currently pay dividends.
What is Gri Bio, Inc.’s EPS estimate?
Gri Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gri Bio, Inc. have?
Gri Bio, Inc. has 10,121,060 shares outstanding.
What happened to Gri Bio, Inc.’s price movement after its last earnings report?
Gri Bio, Inc. reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.31. Following the earnings report the stock price went up 3.175%.
Which hedge fund is a major shareholder of Gri Bio, Inc.?
Currently, no hedge funds are holding shares in GRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gri Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Stock 12 Month Forecast
Average Price Target
$23.00
▲(1021.95% Upside)
Technical Analysis
Ownership Overview
17.52%
Insiders
0.81% Mutual Funds
3.08% Other Institutional Investors
78.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---